The phase Ib JAVELIN Renal 100 study evaluates combination treatment comprising axitinib and avelumab in patients with advanced renal cell carcinoma. At the cut-off date in April 2017, 58% of a total of 55 patients had confirmed objective responses. Among all patients, 58% had grade ≥3 treatment-related adverse events. Five patients died owing to disease progression and one patient died of treatment-related autoimmune myocarditis. The maximum tolerated combination dose was 5 mg twice daily for axitinib and 10 mg/kg every 2 weeks for avelumab.
References
Choueiri, T. K. et al. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. Lancet Oncol. https://doi.org/10.1016/S1470-2045(18)30107-4 (2018)
Rights and permissions
About this article
Cite this article
Thoma, C. Combining targeted and immunotherapy. Nat Rev Urol 15, 263 (2018). https://doi.org/10.1038/nrurol.2018.43
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2018.43
This article is cited by
-
Identification of biomarkers of hepatocellular carcinoma gene prognosis based on the immune-related lncRNA signature of transcriptome data
Functional & Integrative Genomics (2023)
-
High Hepcidin expression predicts poor prognosis in patients with clear cell renal cell carcinoma
Diagnostic Pathology (2022)